MX2020004643A - Composiciones y metodos para mejorar la funcion visual. - Google Patents

Composiciones y metodos para mejorar la funcion visual.

Info

Publication number
MX2020004643A
MX2020004643A MX2020004643A MX2020004643A MX2020004643A MX 2020004643 A MX2020004643 A MX 2020004643A MX 2020004643 A MX2020004643 A MX 2020004643A MX 2020004643 A MX2020004643 A MX 2020004643A MX 2020004643 A MX2020004643 A MX 2020004643A
Authority
MX
Mexico
Prior art keywords
opsin
visual function
compositions
individual
methods
Prior art date
Application number
MX2020004643A
Other languages
English (en)
Inventor
Ehud Y Isacoff
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2020004643A publication Critical patent/MX2020004643A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona un método para restaurar o mejorar la función visual en un individuo, tal método comprende administrarle al individuo un ácido nucleico que comprende una secuencia de nucleótidos que codifica una o más de una opsina del cono de longitud 5 de onda media (opsina MW), una opsina del cono de longitud de onda larga (opsina LW) y una opsina del cono de longitud de onda corta (opsina SW), una o más de la opsina MW, la opsina LW y/ la opsina SW se expresa en una célula de la retina en el individuo, por lo cual se mejora y restaura de este modo la función visual.
MX2020004643A 2017-11-13 2018-11-13 Composiciones y metodos para mejorar la funcion visual. MX2020004643A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762585237P 2017-11-13 2017-11-13
US201762589476P 2017-11-21 2017-11-21
US201862641783P 2018-03-12 2018-03-12
PCT/US2018/060669 WO2019094904A1 (en) 2017-11-13 2018-11-13 Compositions and methods for enhancing visual function

Publications (1)

Publication Number Publication Date
MX2020004643A true MX2020004643A (es) 2021-01-29

Family

ID=66438686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004643A MX2020004643A (es) 2017-11-13 2018-11-13 Composiciones y metodos para mejorar la funcion visual.

Country Status (12)

Country Link
US (2) US10745453B2 (es)
EP (1) EP3709871A4 (es)
JP (2) JP2021502331A (es)
KR (1) KR20200087782A (es)
CN (1) CN111417339A (es)
AU (1) AU2018365175A1 (es)
BR (1) BR112020009329A2 (es)
CA (1) CA3080146A1 (es)
IL (1) IL274176A (es)
MX (1) MX2020004643A (es)
SG (1) SG11202003778QA (es)
WO (1) WO2019094904A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3144986A1 (en) * 2019-06-27 2020-12-30 University Of Florida Research Foundation, Incorporated Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
CN111445483B (zh) * 2020-03-25 2024-11-05 哈尔滨医科大学 一种智能体双模态视觉行为监控系统
WO2022223644A2 (en) * 2021-04-20 2022-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for treating retinal degenerative disorders
CA3221439A1 (en) * 2021-05-26 2022-12-01 Sparingvision G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
WO2023196746A1 (en) * 2022-04-04 2023-10-12 The Regents Of The University Of California Compositions and methods for enhancing visual function
US20240266008A1 (en) * 2023-02-01 2024-08-08 Unlearn.AI, Inc. Systems and Methods for Designing Augmented Randomized Trials
CN118791624B (zh) 2023-04-11 2026-04-03 苏州星明优健生物技术有限公司 用于治疗视网膜神经退行性疾病的新型gpcr嵌合视蛋白
WO2025022144A1 (en) * 2023-07-26 2025-01-30 Sorbonne Universite Chimeric promoter for targeted expression in aii amacrine cells
CN120230798A (zh) * 2023-12-29 2025-07-01 上海朗昇生物科技有限公司 用于视网膜基因递送的重组腺相关病毒载体及其应用
WO2025214507A1 (zh) * 2024-09-03 2025-10-16 中眸医疗科技(武汉)有限公司 新型光敏感通道蛋白vr3.0及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20080260744A1 (en) * 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
US20120172419A1 (en) * 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
CA2795349C (en) * 2010-04-15 2016-11-29 Seattle Genetics, Inc. Targeted pyrrolobenzodiazepine conjugates
EP3029063B1 (en) * 2011-06-24 2019-10-16 Arctos Medical AG Light-sensitive chimeric gpcr protein
GB201403260D0 (en) * 2014-02-25 2014-04-09 Univ Manchester Treatment of retinal degeneration using gene therapy
EP3800191B1 (en) * 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
AU2016219789B2 (en) * 2015-02-20 2021-03-25 Fondazione Telethon Methods and compositions for treating genetic eye diseases
US10533187B2 (en) * 2015-03-18 2020-01-14 University Of Florida Research Foundation, Incorporated Methods and compositions for restoration of cone function in BCM
WO2017055421A1 (en) * 2015-09-29 2017-04-06 Ist Austria Pancreatic beta-cell proliferation methods and device
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
WO2018134168A1 (en) * 2017-01-17 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of expressing a polynucleotide of interest in the cone photoreceptors

Also Published As

Publication number Publication date
IL274176A (en) 2020-06-30
SG11202003778QA (en) 2020-05-28
US20200339641A1 (en) 2020-10-29
JP2021502331A (ja) 2021-01-28
EP3709871A1 (en) 2020-09-23
CN111417339A (zh) 2020-07-14
EP3709871A4 (en) 2021-12-01
CA3080146A1 (en) 2019-05-19
US20190169244A1 (en) 2019-06-06
RU2020119546A (ru) 2021-12-15
JP2023179527A (ja) 2023-12-19
BR112020009329A2 (pt) 2020-10-13
AU2018365175A1 (en) 2020-05-21
KR20200087782A (ko) 2020-07-21
WO2019094904A1 (en) 2019-05-16
US10745453B2 (en) 2020-08-18
RU2020119546A3 (es) 2022-03-23

Similar Documents

Publication Publication Date Title
MX2020004643A (es) Composiciones y metodos para mejorar la funcion visual.
AR098693A1 (es) Método para producir células del epitelio pigmentario retiniano (rpe)
MX2024006041A (es) Celulas t modificadas y metodos para hacer y usar las mismas.
PY18107830A (es) Variantes de alfa-amilasa y polinucleótidos que las codifican
CO2017004728A2 (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)
UY33654A (es) Gen rf4 restaurador de esterilidad masculina citoplasmática (cms) tipo c en el maíz, marcadores mol eculares y uso de los mismos
AR100606A1 (es) Variantes de lipasas y polinucleótidos que las codifican
AR069894A1 (es) Plantas con mayor rendimiento produciendo un knock out (silenciamiento) en genes relacionados con la eficiencia en el uso de nitrogeno (ko nue)"
ECSP19090449A (es) Composiciones y métodos para incrementar la vida útil del banano
MX2018010828A (es) Medio para formar colonias y uso de este.
BR112016026136A2 (pt) composições e métodos para aumentar o desenvolvimento e o rendimento vegetal
PY18107826A (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
MX377211B (es) Composiciones terapéuticas para usarse en el tratamiento del cáncer.
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
AR114072A1 (es) Plantas con genes dhs modificados
CL2021000485A1 (es) Una cepa mutante de salmonella enteritidis; procedimiento para generar la cepa mutante; vacuna recombinante aviar de salmonella enteritidis, divisional de la solicitud 201903108
UY34623A (es) Extracción de adn del pericarpio y determinación del matrilinaje
MX2017007103A (es) Variantes de lipasa y polinucleotidos que las codifican.
ECSP23095204A (es) Composiciones y métodos para mejorar la función visual
AR091160A1 (es) Gen dirigent eg261 y sus ortologos y paralogos y sus usos en la resistencia a patogenos en plantas
AR099006A1 (es) Gen rf3 restaurador tipo s de la esterilidad citoplasmática masculina del maíz (cms)
MX382651B (es) Composiciones, organismos, sistemas y métodos para cítricos resistentes a patógenos
BR112017024855A2 (pt) métodos de produção de aldc
AR100673A1 (es) Enzimas de citoquinina sintasa, constructos y métodos relacionados
UY37294A (es) Promotor vegetal y 3# utr para la expresión de transgenes